login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
INFLARX NV (IFRX) Stock News
USA
- NASDAQ:IFRX -
NL0012661870
-
Common Stock
1.46
USD
+0.14 (+10.61%)
Last: 10/31/2025, 8:00:02 PM
1.57
USD
+0.11 (+7.53%)
After Hours:
10/31/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IFRX Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: Benzinga
- Mentions:
AMGN
BIIB
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
12 days ago - By: InflaRx N.V.
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
2 months ago - By: InflaRx N.V.
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
2 months ago - By: Benzinga
- Mentions:
ALEC
TNYA
RNXT
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
2 months ago - By: InflaRx N.V.
InflaRx Announces Participation in September Investor Conferences
3 months ago - By: Zacks Investment Research
- Mentions:
MGTX
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates
3 months ago - By: InflaRx N.V.
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: InflaRx N.V.
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
3 months ago - By: Yahoo Finance
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected
4 months ago - By: InflaRx N.V.
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
5 months ago - By: InflaRx N.V.
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
5 months ago - By: InflaRx N.V.
InflaRx to Participate in Upcoming Investor Conferences
6 months ago - By: InflaRx N.V.
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
6 months ago - By: Zacks Investment Research
- Mentions:
ALGS
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
6 months ago - By: InflaRx N.V.
InflaRx to Report First Quarter 2025 Results on May 7, 2025
7 months ago - By: Yahoo Finance
- Mentions:
NI
CVAC
NU
JMIA
...
NiSource Inc. (NI): Jim Cramer Says He Likes This Utility Dividend Stock
7 months ago - By: Yahoo Finance
- Mentions:
KRC
CVAC
COMP
TSLA
...
Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?
8 months ago - By: InflaRx N.V.
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
8 months ago - By: InflaRx N.V.
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
8 months ago - By: InflaRx N.V.
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
8 months ago - By: InflaRx N.V.
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
9 months ago - By: InflaRx N.V.
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Please enable JavaScript to continue using this application.